The Biotech Growth Trust (LON:BIOG) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?

The Biotech Growth Trust PLC (LON:BIOG) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 958.04 ($12.06) and traded as low as GBX 850.45 ($10.70). The Biotech Growth Trust shares last traded at GBX 852 ($10.72), with a volume of 48,347 shares changing hands.

The Biotech Growth Trust Trading Down 0.4 %

The company has a debt-to-equity ratio of 11.02, a quick ratio of 0.00 and a current ratio of 0.59. The business has a fifty day simple moving average of GBX 869.02 and a 200 day simple moving average of GBX 958.04. The stock has a market capitalization of £243.41 million, a price-to-earnings ratio of 2.86 and a beta of 0.50.

The Biotech Growth Trust (LON:BIOG) last issued its quarterly earnings data on Wednesday, November 27th. The company reported GBX 0.20 ($0.00) EPS for the quarter. The Biotech Growth Trust had a return on equity of 26.96% and a net margin of 95.33%.

Insider Transactions at The Biotech Growth Trust

In related news, insider Nicola Shepherd bought 1,000 shares of The Biotech Growth Trust stock in a transaction dated Monday, January 13th. The shares were bought at an average cost of GBX 846 ($10.65) per share, with a total value of £8,460 ($10,648.21). Also, insider Hamish Baillie acquired 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were acquired at an average price of GBX 931 ($11.72) per share, with a total value of £27,930 ($35,154.19). In the last three months, insiders have purchased 6,222 shares of company stock valued at $5,659,584. 0.71% of the stock is owned by corporate insiders.

About The Biotech Growth Trust

The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).